Biogen Inc vs MINISO Group Holding Ltd — how do they compare? Biogen Inc trades at $204 (market cap $30.13B), while MINISO Group Holding Ltd trades at $11.97 (market cap $3.62B). The key difference: Biogen Inc is far larger — about 8.3× MINISO Group Holding Ltd's market cap, and MINISO Group Holding Ltd pays a 5.53% dividend while Biogen Inc pays none. Which is the better fit depends on your goals.
| BIIB | MNSO | |
|---|---|---|
Market Cap | $30.13B | $3.62B |
Sector | Health | Technology |
52-Week High | $216.63 | $26.63 |
52-Week Low | $128.93 | $11.30 |
Enterprise Value | $37.20B | $4.29B |
Dividend Yield | — | 5.53% |
Trailing returns across standard periods
Biogen and Idec merged in 2003, combining forces to market Biogen's multiple sclerosis drug Avonex and Idec's cancer drug Rituxan. Today, Rituxan and next-generation antibody Gazyva are marketed via a collaboration with Roche. Biogen also markets novel MS drugs Plegridy, Tysabri, Tecfidera, and Vumerity. In Japan, Biogen's MS portfolio is co-promoted by Eisai. Hemophilia therapies Eloctate and Alprolix (partnered with SOBI) were spun off as part of Bioverativ in 2017. Biogen has several drug candidates in phase 3 trials in neurology and neurodegenerative diseases and has launched Spinraza with partner Ionis. Aduhelm was approved as the firm's first Alzheimer's disease therapy in June 2021.
Read more on BIIB →MINISO Group Holding Ltd is a global lifestyle product retailer known for its aesthetically pleasing, high-quality, and low-cost goods. The company operates a network of branded stores worldwide, offering a diverse range of merchandise, including household goods, cosmetics, toys, and digital accessories. MINISO's business model emphasizes rapid product iteration, efficient supply chain management, and a joint venture and franchise partner network to facilitate its global expansion.
Read more on MNSO →